PWPaul J. Wang

Paul J. Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul J. Wang has a total of 453 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Atrial Fibrillation Ablation Effectiveness End Points, Safety End Points, and Trial Design: Academic Research Consortium Initiative Endorsed by the Heart Rhythm Society

    by Paul J. Wang, Edward P. Gerstenfeld, Jonathan P. Piccini, Atul Verma, T. Jared Bunch, Carina Blomstrom-Lundqvist, Stylianos Tzeis, Jason G. Andrade, A. John Camm, Lin Yee Chen, et al.

    The aim of the AFA-ARC (Atrial Fibrillation Ablation Academic Research Consortium) initiative is to reexamine trial design and the safety and effectiveness end points for pivotal clinical trials evaluating catheter ablation for the treatment of symptomatic atrial fibrillation to provide meaningful and interpretable data to support regulatory decision-making. Beginning in July 2024, a group of international experts began meeting regularly both virtually together and separately in working groups (group 1 effectiveness end points; group 2 safety end points; and group 3 trial design and report forms), with one in-person meeting held in April 2025, and revisions of draft proposals from January 2025 to February 2026. The Food and Drug Administration Office of Cardiovascular Devices at the Center for Devices and Radiological Health provided input throughout the revision and proposal process. A patient advocate participated in the in-person meeting and during the revision phase. Heart Rhythm Society leadership was involved throughout the process and in the revision phase. Industry representatives were sent drafts of the proposed manuscripts during the revision phase before submission. The result of this process was the creation of a combined document to reexamine trial design and the safety and effectiveness end points for pivotal clinical trials evaluating catheter ablation of atrial fibrillation. This document represents contributions from each of the 3 Working Groups. The Heart Rhythm Society endorsed this document. This AFA-ARC document proposes revised effectiveness and safety end points, study design, and report forms for studies evaluating AF ablation in patients with symptomatic paroxysmal, persistent, or longstanding persistent AF.


  • Open Access

    A Guideline-Integrated Remote Monitoring Platform for Hypertension: Feasibility and Preliminary Clinical Outcomes from Two Prospective Single-Arm Pilot Studies of HrtEx (Preprint)

    by Meghedi Bhabakanian, Samuel Asher Miller, Tania Chen, Vishnu Ravi, Jered Miller, Kathleen Lacar, Larry Frye, Jessica Kennedy, Kevin Wasserstein, Mintu Turakhia, et al.

    BACKGROUND Hypertension affects nearly half of US adults, yet fewer than one in four achieves adequate blood pressure (BP) control. Traditional outpatient management is limited by infrequent visits and episodic BP measurement, contributing to therapeutic inertia. Remote patient monitoring (RPM) enables home-based BP tracking but can overwhelm clinicians with unstructured data, exacerbating administrative burden. Guideline-integrated decision support that automates BP interpretation and generates medication titration recommendations could reduce therapeutic inertia while preserving clinician oversight. OBJECTIVE This study was conducted to evaluate the feasibility, acceptability, and preliminary effectiveness of the HrtEx hypertension management platform in distinct care environments. METHODS We conducted two prospective single-arm pilot studies of HrtEx, a clinician-facing digital decision support platform that converts home BP data into guideline-concordant medication titration recommendations. The first pilot (HrtEx 1.0; n=18) was conducted at an urban academic medical center; the second (HrtEx 2.0; 19 enrolled, 15 analyzed) at a rural cardiology clinic. Adults with essential hypertension (BP >130/80 mmHg) treated with 2 or fewer antihypertensive medications measured home BP daily using Bluetooth-enabled cuffs with automated transmission. BP values were averaged over 2-week intervals; sustained elevations triggered guideline-based titration recommendations that clinicians could accept or decline. The primary outcome was 12-week change in systolic and diastolic BP; clinician acceptance rate of algorithm-generated recommendations was assessed as a secondary outcome in HrtEx 2.0. RESULTS In the academic pilot, mean systolic BP (SBP) decreased from 133.1 ± 7.8 to 121.3 mmHg (Δ −11.8 mmHg; 95% CI, 5.8 to 17.9; p<0.001) and mean diastolic BP (DBP) from 87.3 ± 7.1 to 80.2 mmHg (Δ −7.1 mmHg; 95% CI, 3.1 to 11.1; p=0.002). In the rural pilot, among the 15 participants with elevated baseline BP, mean SBP decreased from 133.9 to 124.7 mmHg (Δ −9.2 mmHg; 95% CI, 4.6 to 13.8; p=0.0008; d=1.10) and mean DBP from 79.0 to 76.1 mmHg (Δ −2.9 mmHg; 95% CI, 0.8 to 5.1; p=0.012; d=0.75). In Pilot 2, clinicians accepted 32 of 38 (84%) algorithm-generated titration recommendations, averaging 2.1 accepted adjustments per analyzed patient (32 accepted recommendations across 15 analyzed patients); clinician recommendation tracking was not implemented in Pilot 1. Patient adherence exceeded 89% in both cohorts; 100% of surveyed Pilot 2 participants expressed satisfaction with medication titration timing. CONCLUSIONS Across two geographically and demographically distinct single-arm pilot studies, a guideline-integrated RPM decision support platform demonstrated feasibility and was associated with systolic BP reductions of 11.8 mmHg and 9.2 mmHg in academic and rural cohorts, respectively, alongside high clinician acceptance and patient adherence. Given the absence of a comparator arm, these findings are hypothesis-generating and support confirmatory evaluation in randomized controlled trials. CLINICALTRIAL NCT05479461

  • Open Access

    Feasibility of Noninvasive Atrial and Ventricular Activation, Conduction-Velocity, and Site-of-Origin Mapping with Solid-State Magnetocardiography: A Preclinical Validation Study

    by Kelly A. Brennan, Sabyasachi Bandyopadhyay, Charles Sillett, Jennifer K. Lyons, Makoto Kameno, Yasushi Terazono, Prasanth Ganesan, Xichong Liu, Gentaro Ikeda, Hiroyuki Takashima, et al.

    Background: Characterizing cardiac activation by its site of origin, propagation, and conduction velocity underlies arrhythmia diagnosis and management, but invasive electrophysiology (EP) mapping requires vascular access, fluoroscopy, and sedation. Magnetocardiography (MCG) enables contactless mapping, and recent solid-state sensors remove the cost, cryogenic, and shielding barriers of legacy systems. We assessed the feasibility of a novel solid-state MCG system for noninvasive arrhythmia site-of-origin (SOO) localization and activation reconstruction, benchmarked against electrocardiographic imaging (ECGi). Methods: In nine swine implanted with right atrial and right ventricular pacing leads, we recorded MCG and ECGi simultaneously during atrial and ventricular pacing. Invasive epicardial contact EP mapping provided the activation-time reference and MRI-derived lead-tip location the SOO reference. Local activation time (LAT), conduction velocity (CV), and SOO were compared on a co-registered chamber mesh. SOO error was the Euclidean distance to the MRI lead tip; LAT and CV agreement with EP were quantified by Pearson r and compared using Wilcoxon signed-rank tests. Results: Across 17 datasets (8 atrial, 9 ventricular), median SOO error was lower for MCG than ECGi in the atrium (19.6 vs 31.2 mm; p=0.023) and ventricle (12.0 vs 26.1 mm; p=0.074). LAT agreement with EP was comparable between modalities and higher in the ventricle (MCG r=0.63; ECGi r=0.68) compared with the atrium (MCG r=0.40; ECGi r=0.53), each correlating with invasive EP mapping above chance. CV agreement was modest and numerically higher for MCG in the ventricle. Conclusions: Solid-state MCG was feasible for noninvasive site-of-origin localization and activation mapping, with accuracy comparable to ECGi, motivating larger prospective studies to define its clinical role in noninvasive mapping. Clinical Perspective: What Is Known: Invasive electrophysiology mapping is the reference standard for localizing the arrhythmia site of origin and characterizing cardiac activation, but it requires vascular access, fluoroscopy, and prolonged sedation within the electrophysiology laboratory. Existing noninvasive options have important limitations: electrocardiographic imaging depends on concomitant thoracic imaging, size-dependent vest fit, and torso-conductivity modeling, while legacy magnetocardiography has required costly cryogenic and magnetically shielded infrastructure. What the Study Adds: In a preclinical large-mammal model referenced to invasive electrophysiology and MRI, a novel contactless solid-state magnetocardiography system feasibly localized atrial and ventricular sites of origin and reconstructed activation without body-surface electrodes. Magnetocardiography localized the site of origin more accurately than ECGi in the atrium, and showed numerically lower localization error in the ventricle. Magnetocardiography displayed activation-time and conduction-velocity agreement with invasive electrophysiology comparable to electrocardiographic imaging in both chambers. Solid-state magnetocardiography may offer a scalable, noninvasive approach for preprocedural localization and complementary activation mapping, motivating larger prospective clinical validation.

  • Identifying the Presence and Characteristics of Mid-Myocardial and Epicardial Fibrosis From Intracardiac Electrograms in Patients Undergoing Ventricular Arrhythmia Ablation Using a Transformer-Based Self-Supervised Classifier

    by Xichong Liu, Abdul Qayyum, Sabyasachi Bandyopadhyay, Sulaiman Somani, Prasanth Ganesan, Rayan Ansari, Hui Ju Chang, Alexander C. Perino, Nitish Badhwar, Paul J. Wang, et al.

    BACKGROUND: Catheter ablation is an essential tool for ventricular arrhythmia management, yet sustained procedural success is hindered by the limited ability to identify nonendocardial arrhythmogenic substrates during the procedure. Although delayed enhancement cardiac magnetic resonance imaging is the reference standard for detecting myocardial fibrosis, barriers including cost, workflow complexity, and artifacts in patients with implantable devices limit its preprocedural use. We hypothesized that intracardiac electrograms provide sufficient information to infer scar beyond the endocardial surface and that this information can be harnessed by machine learning techniques. METHODS: This retrospective study included a total of 131 584 cardiac contact electrogram (EGM) signals collected from 46 patients undergoing ventricular arrhythmia ablation. A stratified patient-wise split was used to create the training/validation set (N=37) and the testing set (N=9), while ensuring a similar distribution of scar types. We developed a novel image-processing workflow to create scar labels using coregistered cardiac magnetic resonance imaging and electroanatomic mapping surface meshes. We developed a transformer-based self-supervised model, EGM2Scar-AI, alongside basic convolutional neural network models using either EGM waveforms or EGM-derived short-time Fourier transform spectrograms. RESULTS: The average task-specific area under the receiver operating characteristic curve of both the basic and short-time Fourier transform-based convolutional neural networks was 0.729 (0.725–0.732) and 0.729 (0.726–0.733), respectively, while EGM2Scar-AI performed significantly better with an average area under the receiver operating characteristic curve of 0.822 (0.819–0.825) across all 3 scar types. All models performed better on endocardial and mid-myocardial fibrosis identification, with a modest reduction in performance for epicardial fibrosis. Sensitivity improved significantly with the transformer-based architecture without appreciable changes in specificity. CONCLUSIONS: Our study demonstrates that routine intracardiac electrograms enable the identification of endocardial, mid-myocardial, and epicardial scar using a transformer-based self-supervised deep learning model. Ultimately, our model has the potential to provide magnetic resonance imaging-like fibrosis maps during EP procedures without the need for external imaging and to increase the data set size for patient-specific models in ventricular arrhythmia research.


  • Top Cited Papers

    Deep Learning–Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation

    by Rayan A. Ansari, Sabyasachi Bandyopadhyay, Rishi K. Trivedi, Kelly A. Brennan, Xichong Liu, Prasanth Ganesan, J. Weston Hughes, Alexander C. Perino, Euan A. Ashley, Paul J. Wang, et al.

    BACKGROUND: Drug-induced QT prolongation after successful inpatient loading of class III antiarrhythmics may occur during routine outpatient care. Insertable cardiac monitors offer continuous signals but are limited by single-lead configuration. We hypothesized that a spatially aware deep learning system (3DRECON-QT) can reconstruct spatial information from a single lead vector to quantify QT/QTc and identify high-risk prolongation. METHODS: We developed 3DRECON-QT using a multitask encoder–decoder that ingests a 10-s single-lead signal, reconstructs 12 leads, and predicts QT/QTc. The model was developed using 12-lead ECGs with clinician-adjudicated QT/RR from a large health system and tested in an external center with different ECG hardware. Continuous monitoring performance was assessed in a public dofetilide‐loading data set with serial ECGs. In a real-world cohort of outpatients on dofetilide or sotalol presenting to the hospital or emergency room for any reason, rates of ventricular arrhythmias and QT prolongation were assessed. Device validation was tested in patients with insertable cardiac monitor recordings paired with clinical 12-lead ECGs. RESULTS: 3DRECON-QT classified prolonged QTc from single-lead signals with area under the receiver operating characteristics curve, 0.942 (mean absolute error, 17.5 ms) in the internal test set and 0.943 (mean absolute error, 21.1 ms) externally. During continuous dofetilide monitoring, predictions correlated with ground truth ( r , 0.851; mean absolute error, 17.8 ms; area under the receiver operating characteristics curve, 0.936 for prolonged QTc, 0.816 for ≥15% QTc rise). QTc prediction from true insertable cardiac monitor recordings showed r =0.824 and mean absolute error, 17.5 ms. In outpatients on class III antiarrhythmics (n=1676), 16.5% had high-risk QTc prolongation. Ventricular arrhythmia events were 3.97% versus 0.86% without prolongation (adjusted odds ratio, 4.24 [95% CI, 1.81–9.90]). 3DRECON-QT detected these events with area under the receiver operating characteristics curve 0.94 (F1 score, 0.60). CONCLUSIONS: A single-lead, deep-learning approach can achieve guideline-level measurement accuracy, enable continuous QTc surveillance from nonstandard ECG vectors, and identify clinically meaningful outpatient QTc prolongation associated with a >4-fold increase in serious ventricular arrhythmias. This strategy may enhance safety monitoring after class III antiarrhythmic initiation and support targeted intervention.


  • Comparing Phenotypes for Acute and Long-Term Response to Atrial Fibrillation Ablation Using Machine Learning

    by Prasanth Ganesan, Maxime Pedron, Ruibin Feng, Albert J. Rogers, Brototo Deb, Hui Ju Chang, Samuel Ruiperez-Campillo, Viren Srivastava, Kelly A. Brennan, Wayne R. Giles, et al.

    BACKGROUND: It is difficult to identify patients with atrial fibrillation (AF) most likely to respond to ablation. While any arrhythmia patient may recur after acutely successful ablation, AF is unusual in that patients may have long-term arrhythmia freedom despite a lack of acute success. We hypothesized that acute and chronic AF ablation outcomes may reflect distinct physiology and used machine learning of multimodal data to identify their phenotypes. METHODS: We studied 561 consecutive patients in the Stanford AF ablation registry (66±10 years, 28% women, 67% nonparoxysmal), from whom we extracted 72 data features of electrograms, electrocardiogram, cardiac structure, lifestyle, and clinical variables. We compared 6 machine learning models to predict acute and long-term end points after ablation and used Shapley explainability analysis to contrast phenotypes. We validated our results in an independent external population of n=77 patients with AF. RESULTS: The 1-year success rate was 69.5%, and the acute termination rate was 49.6%, which correlated poorly on a patient-by-patient basis (φ coefficient=0.08). The best model for acute termination (area under the curve=0.86, Random Forest) was more predictive than for long-term outcomes (area under the curve=0.67, logistic regression; P <0.001). Phenotypes for long-term success reflected clinical and lifestyle features, while phenotypes for AF termination reflected electrical features. The need for AF induction predicted both phenotypes. The external validation cohort showed similar results (area under the curve=0.81 and 0.64, respectively) with similar phenotypes. CONCLUSIONS: Long-term and acute responses to AF ablation reflect distinct clinical and electrical physiology, respectively. This de-linking of phenotypes raises the question of whether long-term success operates through factors such as attenuated AF progression. There remains an urgent need to develop procedural predictors of long-term AF ablation success.


  • Who are we missing? Language exclusivity of patient‐reported outcomes in atrial fibrillation clinical trials

    by Roy H. Lan, Eduardo Perez Guerrero, Eldrin F. Lewis, Paul J. Wang

    Introduction: Patient‐reported outcomes (PROs) are increasingly used to evaluate quality of life (QoL) in Atrial Fibrillation (AF) patients, providing crucial insights in clinical trials. This study examines the frequency of PRO use in AF trials and the linguistic accessibility of AF‐specific PROs.Background: As the United States becomes more multilingual, ensuring PROs are available in various languages is vital. The number of people speaking a language other than English at home has tripled from 23.1 million in 1980 to 67.8 million in 2019. This diversity necessitates the availability of PROs in multiple languages for inclusive clinical assessments.Methods: We queried ClinicalTrials.gov for all US interventional AF trials up to November 28, 2023, reviewing each for PRO usage as primary or secondary outcomes. We identified the five most common AF‐specific and generic PROs, extracting their available translations and original languages from published sources.Results: Of 233 identified trials, 191 had associated publications, with 180 (94.2%) conducted solely in English. Only one trial (0.4%) used an AF‐specific PRO as a primary outcome, compared to four (1.7%) with a generic PRO. Ten trials (4.3%) used AF‐specific PROs as secondary endpoints, versus 22 (9.4%) using generic PROs. AF‐specific PROs had significantly fewer translations than generic PROs (11.2 vs. 148.8; p < .001). The AF Effect on Quality‐of‐Life (AFEQT) was available in 24 languages, with limited translations in commonly spoken US languages like Arabic and Asian languages.Conclusion: The limited availability of AF‐specific PRO translations highlights a barrier to inclusive AF clinical trials. Expanding translations for AF‐specific PROs is crucial for equitable QoL assessments.


  • Women Trainees in Electrophysiology and the Effect of Role Models

    by Tina Baykaner, Shana Greif, Ramya S. Vajapey, Christine M. Albert, Zaid Aziz, Nitish Badhwar, T. Jared Bunch, Jim W. Cheung, Jonathan Chrispin, Mina K. Chung, et al.


  • Diversity in atrial fibrillation trials: Assessing the role of language proficiency as a recruitment barrier

    by Roy H. Lan, Eduardo Perez Guerrero, Sa Shen, FeiFei Qin, Victor Ritter, Cati Brown-Johnson, Kira Clark, Erin Rose, Eldrin F. Lewis, Paul J. Wang

  • Open Access

    Design and Implementation of an Electronic Health Record‐Integrated Hypertension Management Application

    by Mario Funes Hernandez, Meghedi Babakhanian, Tania P. Chen, Ashish Sarraju, Clark Seninger, Vishnu Ravi, Zahra Azizi, James Tooley, Tara I. Chang, Ying Lu, et al.

    Background: High blood pressure affects approximately 116 million adults in the United States. It is the leading risk factor for death and disability across the world. Unfortunately, over the past decade, hypertension control rates have decreased across the United States. Prediction models and clinical studies have shown that reducing clinician inertia alone is sufficient to reach the target of ≥80% blood pressure control. Digital health tools containing evidence‐based algorithms that are able to reduce clinician inertia are a good fit for turning the tide in blood pressure control, but careful consideration should be taken in the design process to integrate digital health interventions into the clinical workflow. Methods: We describe the development of a provider‐facing hypertension management platform. We enumerate key steps of the development process, including needs finding, clinical workflow analysis, treatment algorithm creation, platform design and electronic health record integration. We interviewed and surveyed 5 Stanford clinicians from primary care, cardiology, and their clinical care team members (including nurses, advanced practice providers, medical assistants) to identify needs and break down the steps of clinician workflow analysis. The application design and development stage were aided by a team of approximately 15 specialists in the fields of primary care, hypertension, bioinformatics, and software development. Conclusions: Digital monitoring holds immense potential for revolutionizing chronic disease management. Our team developed a hypertension management platform at an academic medical center to address some of the top barriers to adoption and achieving clinical outcomes. The frameworks and processes described in this article may be used for the development of a diverse range of digital health tools in the cardiovascular space.